Vasospasm & Delayed Cerebral Ischemia After SAH

Delayed cerebral ischemia (DCI) remains the leading cause of preventable death and disability after aneurysmal subarachnoid hemorrhage (aSAH), affecting approximately 20–30% of patients during the critical days 4–14 window. For decades, DCI was considered synonymous with large-vessel vasospasm — a paradigm that has fundamentally shifted. We now understand that vasospasm is only one component of a multifactorial process that includes microthrombosis, cortical spreading depolarizations, blood-brain barrier disruption, and neuroinflammation. This distinction is clinically important: reducing angiographic vasospasm alone does not reliably improve functional outcomes, as the clazosentan program (CONSCIOUS-1, CONSCIOUS-2, CONSCIOUS-3, REACT) dramatically demonstrated. Despite decades of research, nimodipine remains the only pharmacologic therapy proven to improve functional outcomes, likely through neuroprotective mechanisms beyond simple vasodilation.

1. Monitoring & Detection of Vasospasm

Early detection of vasospasm and evolving DCI is essential because treatment is most effective before infarction occurs. Multimodal monitoring combines clinical assessment with one or more of the following tools:

2. Nimodipine: The Only Proven Therapy

Nimodipine, an L-type calcium channel blocker with selective cerebral vascular activity, is the only FDA-approved drug for improving neurological outcomes after aSAH. The evidence base rests on two landmark trials from the 1980s:

• Allen et al. (1983): First placebo-controlled trial showing nimodipine reduced the incidence of severe neurological deficit from cerebral vasospasm (1.8% vs 8.3%).
• British Aneurysm Nimodipine Trial (1989): 554 patients. Nimodipine 60 mg PO q4h × 21 days reduced cerebral infarction from 33% to 22% (p=0.03) and improved 3-month outcomes (GOS). This trial established the standard dosing regimen still used today.

A Cochrane meta-analysis pooling all nimodipine trials confirmed a reduction in poor outcome (RR 0.67; 95% CI 0.55–0.81) and secondary ischemia (RR 0.66; 95% CI 0.46–0.95). Importantly, nimodipine does not consistently reduce angiographic vasospasm — its benefit is likely mediated through neuroprotective mechanisms (reduced calcium influx, improved microcirculation, anti-inflammatory effects) rather than direct vasodilation of large vessels.

3. Clazosentan: The Vasospasm–DCI Disconnect

The clazosentan program represents one of the most instructive stories in SAH pharmacotherapy. Clazosentan is a selective endothelin-A receptor antagonist that potently reduces large-vessel vasospasm — but despite this, it has consistently failed to improve functional outcomes in Western populations. This disconnect reshaped our understanding of DCI pathophysiology.

3.1 Trial Results

CONSCIOUS-3 is the most provocative result: clazosentan 15 mg/h dramatically reduced vasospasm-related morbidity and mortality (the composite endpoint including DCI, rescue therapy, new infarct, and death) — yet this did not translate into better functional outcomes at 12 weeks. This finding implies that even when large-vessel vasospasm is effectively prevented, other mechanisms of brain injury continue to drive poor outcomes. The REACT trial (2024), the most recent phase 3 effort, similarly failed to demonstrate benefit on its primary endpoint of clinical deterioration from DCI.

Clazosentan is currently approved in Japan and South Korea, where two phase 3 trials (in Japanese patients) did show a reduction in vasospasm-related morbidity and all-cause mortality. Real-world Japanese data are encouraging, with some cohorts showing reduced vasospasm-related infarction. Whether the discrepancy between Japanese and Western trial results reflects pharmacogenomic differences, practice pattern variations, or chance remains unclear.

Safety concerns with clazosentan include pulmonary complications (fluid overload, pleural effusions), hypotension, anemia, and hepatotoxicity — effects consistent with endothelin receptor antagonism. These require careful monitoring, particularly in elderly or hepatically impaired patients.

4. Failed & Ineffective Therapies

Numerous agents have been tested for DCI prevention and failed in adequately powered trials. Understanding these failures is important to avoid repeated use of ineffective therapies in clinical practice.

4.1 Magnesium Sulfate

Magnesium was one of the most promising DCI prevention candidates, with strong preclinical rationale (vasodilation, NMDA receptor antagonism, neuroprotection). Two definitive RCTs settled the question:

• IMASH (2010): 327 patients. MgSO₄ 80 mmol/day × 10–14 days vs. saline. No difference in favorable outcome (GOSE 5–8): 64% MgSO₄ vs 63% saline (OR 1.0; 95% CI 0.7–1.6). No subgroup benefited.
• MASH-2 (2012): 1,203 patients — the largest SAH pharmacotherapy trial. MgSO₄ 64 mmol/day × 20 days vs. placebo. Poor outcome (mRS 4–6): 26.2% MgSO₄ vs 25.3% placebo (RR 1.03; 95% CI 0.85–1.25). An updated IPD meta-analysis of 2,047 patients confirmed no benefit (RR 0.96; 95% CI 0.84–1.10).

Verdict: IV magnesium does not improve outcomes after aSAH. It should not be administered for DCI prevention (AHA 2023: Class 3: No Benefit, LOE A).

4.2 Statins

Several small trials suggested that acute statin initiation might reduce vasospasm and DCI after aSAH, generating significant enthusiasm. The definitive trial was HDS-SAH:

• HDS-SAH (2015): 255 patients. High-dose simvastatin 80 mg vs. 40 mg daily × 21 days. No difference in delayed ischemic deficit (27% vs 24%, OR 1.2, p=0.586), favorable outcome (mRS 0–2: 73% vs 72%, NS), or clinical vasospasm (15% vs 12%, NS).
• A Cochrane meta-analysis (2013) of all statin trials in SAH found no significant benefit on mortality, DCI, or vasospasm.

Verdict: Statin initiation specifically for DCI prevention is not recommended. Continue statins if patients are already on them for other indications (AHA 2023: Class 3: No Benefit, LOE B-R for initiating statins specifically for aSAH).

4.3 Albumin

• ALISAH (2012): Dose-escalation study in 47 patients. 25% albumin at 0.625–1.875 g/kg/day × 7 days. Doses up to 1.25 g/kg/day were tolerated; higher doses caused pulmonary edema requiring early termination. Phase 3 was not pursued.

4.4 Aspirin

• MASH (2006): 161 patients. ASA 100 mg daily × 14 days vs. placebo. ASA did not reduce DIND (23% vs 15%, HR 1.83 — numerically worse with ASA). Stopped early for futility. Possible harm from impaired platelet function in acutely hemorrhaged patients.

4.5 Other Failed Agents

5. Emerging & Investigational Therapies

Despite the long list of failed agents, several investigational therapies have shown promising signals that warrant further investigation. These target the multifactorial mechanisms of DCI beyond large-vessel vasospasm.

5.1 Tirofiban (ISPASM)

The ISPASM trial (2021) tested whether targeting microthrombosis — a key DCI mechanism — could improve outcomes. This phase 1/2a double-blind, placebo-controlled trial randomized 30 patients with aSAH (treated with coiling + EVD) to IV tirofiban (GPIIb/IIIa inhibitor, 0.10 µg/kg/min × 7 days) or placebo.

The magnitude of the DCI reduction (NNT 3.7) is unprecedented in SAH pharmacotherapy and supports the microthrombosis hypothesis. However, this is a small, single-center, phase 1/2 trial, and the results require confirmation in a larger phase 3 study. The safety profile was acceptable — no increase in intracranial hemorrhage despite antiplatelet therapy in recently hemorrhaged patients.

5.2 Dapsone

The Dapsone in SAH trial tested dapsone (a diaminodiphenylsulfone with anti-inflammatory and neuroprotective properties) vs. placebo in patients with aSAH. Results were striking:

• Vasospasm: 26.9% dapsone vs 63.6% placebo (p=0.011)
• Brain infarction: 19.2% vs 63.6% (p=0.001)
• Favorable mRS at discharge: 76.9% vs 36.4% (p=0.005)
• Favorable mRS at 3 months: 80% vs 38.9% (p=0.019)
• Mortality: 7.7% vs 27.3% (p=0.058)

These effect sizes are extraordinary — arguably the largest treatment effect ever seen in an SAH prevention trial. However, this was a small single-center study and awaits replication. Dapsone's mechanism may involve inhibition of lipid peroxidation and glutamate excitotoxicity rather than direct vascular effects, providing true neuroprotection akin to nimodipine.

5.3 Galantamine (SAHRANG)

The SAHRANG trial (2025) explored an entirely different mechanism — cholinergic modulation. This phase 1/2 dose-escalation study randomized 60 patients with aSAH to galantamine (an acetylcholinesterase inhibitor used in Alzheimer's disease) at 8 mg or 12 mg q12h for 90 days, vs. placebo. Galantamine was as tolerable and safe as placebo. While no significant differences were observed in mRS or MoCA scores, the galantamine group showed significantly greater improvement in quality of life (EQ5D5L VAS) between days 30–60 (10.7-point improvement vs 1.04-point decline, p<0.05). Mortality was numerically lower with galantamine (3.3% vs 13.3%, p=0.34). This trial establishes safety and provides signals worthy of a larger phase 3 study.

5.4 Other Agents Under Investigation

6. Hemodynamic Management

Hemodynamic management in aSAH has undergone a major paradigm shift. The traditional "triple-H therapy" (hypertension, hypervolemia, hemodilution) has been largely abandoned as evidence accumulated that prophylactic hypervolemia is ineffective and potentially harmful (increased cardiac complications, pulmonary edema) while adding nothing to vasospasm prevention. Current practice emphasizes euvolemia with targeted hypertension for symptomatic vasospasm only.

6.1 Goal-Directed Hemodynamic Therapy

The Goal-Directed Hemodynamic Therapy (GDHT) trial (2020) provided the strongest evidence for protocolized hemodynamic management. This single-center RCT randomized 108 aSAH patients to GDHT using transpulmonary thermodilution (PiCCO2) with predefined targets (MAP >70 mmHg, CVP >4 mmHg, GEDI ≥640 mL/m², cardiac index ≥2.5 L/min/m², with induced hypertension to MAP 100–120 mmHg if vasospasm developed) vs. standard care for 10–14 days.

• DCI: 13% GDHT vs 32% control (p=0.021)
• Favorable outcome (GOS=5) at 3 months: 66% vs 44% (p=0.025)
• No difference in vasospasm rates, ICU/hospital length of stay, or mortality
• Hyponatremia: 11% GDHT vs 31% control (p=0.010) — protocolized fluid management prevented excessive free water

This trial demonstrates that structured hemodynamic monitoring and normovolemia-targeting reduces DCI — not by preventing vasospasm itself, but by maintaining adequate cerebral perfusion during the vulnerable period.

6.2 Current Guideline Recommendations

7. CSF Drainage & Blood Clearance

The subarachnoid clot itself is the primary driver of vasospasm and DCI — blood breakdown products (oxyhemoglobin, endothelin-1) directly cause arterial spasm and inflammation. Strategies to accelerate blood clearance from the subarachnoid space have shown some of the most promising results in recent years.

7.1 EARLYDRAIN

The EARLYDRAIN trial was a multicenter RCT that randomized 287 patients with aSAH to early lumbar CSF drainage (5 mL/hour, started within 72 hours, continued up to 8 days) plus standard care vs. standard care alone. This is the largest RCT of CSF drainage for DCI prevention.

• Primary: Unfavorable outcome (mRS 3–6) at 6 months: 32.6% lumbar drain vs 44.8% control (RR 0.73; 95% CI 0.52–0.98; p=0.04)
• Secondary infarctions at discharge: 28.5% vs 39.9% (RR 0.71; 95% CI 0.49–0.99; p=0.04)
• Mortality at 6 months: 13.2% vs 17.5% (NS)
• NNT = 8.3 to prevent one unfavorable outcome

EARLYDRAIN provides the strongest evidence to date that early CSF drainage improves outcomes after aSAH, likely by accelerating clearance of spasmogenic blood products and reducing intracranial pressure. The 2023 AHA guidelines now recommend considering CSF drainage for aSAH (Class 2a, LOE B-R).

7.2 Neurapheresis (PILLAR)

The PILLAR trial (2019) tested a novel approach — active CSF filtration using a dual-lumen lumbar catheter (Neurapheresis system) that filters blood and inflammatory mediators from CSF and returns cleaned CSF to the thoracic subarachnoid space. In 13 patients: CSF red blood cells decreased by ~53%, total protein by 71%, and CT Hijdra score by ~47%. No serious device-related adverse events occurred. The PILLAR-XT extension study is ongoing. While still investigational, this represents a mechanistically compelling approach to the root cause of vasospasm.

8. Endovascular Rescue Therapy

When medical management (nimodipine + induced hypertension) fails to reverse clinical vasospasm, endovascular rescue is the next step. Two main approaches are used:

8.1 Balloon Angioplasty

Mechanical dilation of vasospastic segments using compliant balloons. Most effective for proximal large-vessel spasm (ICA, MCA M1, basilar trunk). Produces immediate, durable vasodilation. Risks include vessel rupture (~1–5%), dissection, and reperfusion injury. AHA 2023: reasonable for symptomatic vasospasm refractory to medical therapy (Class 2a, LOE B-NR).

8.2 Intra-arterial Vasodilators

Direct injection of vasodilators into spastic arteries via microcatheter:

• Nicardipine: Most commonly used (1–5 mg per vessel territory). Effective for both proximal and distal vasospasm.
• Verapamil: Alternative calcium channel blocker (5–20 mg per territory). Similar efficacy.
• Milrinone: PDE3 inhibitor. Can be given intra-arterially or as a continuous IV infusion (Montreal protocol: 0.75–1.25 µg/kg/min). Retrospective data: IA nimodipine was superior to milrinone monotherapy for vessel dilation, but combination nimodipine + milrinone was effective in severe cases.

8.3 Continuous Intra-arterial Nimodipine (CIAN)

The CIAN study (2022) evaluated continuous IA nimodipine infusion (0.5–2.0 mg/h via microcatheter in the extracranial ICA/VA) for a median of 5 days in 17 patients with severe, refractory large-vessel vasospasm. Favorable outcome (GOS 4–5) was achieved in 76% at 1 year, with DCI-related infarctions in 47% (5 minor, 3 major). While observational, these results suggest that prolonged IA nimodipine may rescue patients with the most severe vasospasm — though at significant resource cost and procedural complexity.

9. SAH Headache Management

Severe headache is ubiquitous in aSAH and a significant source of suffering. Opioid use is common but carries risks of respiratory depression, sedation (masking neurological changes), constipation, and dependence. Non-pharmacologic approaches are being explored:

• VANQUISH (2024): Multicenter randomized double-blind pilot study of noninvasive vagus nerve stimulation (nVNS, GammaCore) vs. sham in SAH patients with severe headache (VAS ≥7). nVNS significantly reduced post-stimulation headache intensity (p=0.005) but did not significantly reduce morphine equivalent dose (10% at day 7, 15% at day 14 — both NS). The only notable adverse effect was increased nausea with nVNS (16.7% vs 2.0%). This establishes feasibility and provides a signal for a larger efficacy trial.

Acetaminophen and ice packs remain first-line. IV ketorolac (≤5 days) can be used after aneurysm securing if not contraindicated. Minimize opioids where possible. Nerve blocks (greater occipital, supraorbital) are used at some centers as opioid-sparing adjuncts.

10. Trial Comparison Table

References

1. Pickard JD, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298(6674):636–642.
2. Macdonald RL, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1). Stroke. 2008;39(11):3015–3021.
3. Macdonald RL, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal SAH undergoing surgical clipping: CONSCIOUS-2. Lancet Neurol. 2011;10(7):618–625.
4. Macdonald RL, et al. Randomized trial of clazosentan in patients with aSAH undergoing endovascular coiling (CONSCIOUS-3). Stroke. 2012;43(6):1463–1469.
5. Araya AQ, et al. REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to DCI after aSAH. J Neurosurg. 2024;142(1):98–107.
6. Wong GKC, et al. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH). Stroke. 2010;41(5):921–926.
7. Dorhout Mees SM, et al. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2). Lancet. 2012;380(9836):44–49.
8. Kirkpatrick PJ, et al. Simvastatin in aneurysmal subarachnoid haemorrhage (HDS-SAH). Lancet Neurol. 2014;13(7):666–675.
9. Dorhout Mees SM, et al. Magnesium and aspirin after subarachnoid haemorrhage (MASH). Neurosurgery. 2006;59(4):OR286.
10. Vergouwen MDI, et al. Albumin in subarachnoid hemorrhage (ALISAH). Neurology. 2012;78(8):e52–e54.
11. Wessell A, et al. ISPASM trial: intravenous tirofiban for DCI prevention. Neurosurgery. 2021;88(6):1136–1143.
12. Hänggi D, et al. EARLYDRAIN: randomized trial of early lumbar CSF drainage in aSAH. Stroke. 2023;54(2):413–420.
13. Mutoh T, et al. Goal-directed fluid management and functional outcome after SAH. Stroke. 2020;51(2):580–587.
14. Hoh BL, et al. 2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage. Stroke. 2023;54(7):e314–e370.
15. Treggiari MM, et al. Guidelines for the Neurocritical Care Management of Aneurysmal Subarachnoid Hemorrhage. Neurocrit Care. 2023;39(1):1–28.